- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 2 Aug 2024
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 17 listed it in both
- Shares listed
- 241,143,482
- combined, among listed positions
- Reported value
- $14.2bn
- combined, at the quarter end
Among the 94 comparable managers: 16 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing CVS in Q2 2024
24 of 24 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 35,455,509 shares now+22,311,687
- Dodge & Coxexisting position · 61,683,343 shares now+20,670,800
- Capital World Investorsexisting position · 56,023,849 shares now+12,246,975
- Glenview Capital Management LLCexisting position · 9,162,389 shares now+7,465,959
- Holocene Advisors LPnew position · 2,738,805 shares now+2,738,805
Reductions
- Fidelity (FMR LLC)existing position · 29,371,944 shares now-5,051,337
- Invesco Ltdexisting position · 12,090,393 shares now-2,546,382
- Bridgewater Associates LPexisting position · 1,243,566 shares now-1,211,051
- T. Rowe Price Associates Incexisting position · 10,236,372 shares now-462,662
- Markel Group Incexisting position · 47,000 shares now-285,000
New positions and exits
New (3)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 19 | $12.0bn | n.a. | n.a. |
| Q3 2013 | 22 | $11.8bn | n.a. | n.a. |
| Q4 2013 | 19 | $14.0bn | n.a. | n.a. |
| Q1 2014 | 17 | $15.3bn | n.a. | n.a. |
| Q2 2014 | 24 | $14.7bn | n.a. | n.a. |
| Q3 2014 | 21 | $15.4bn | n.a. | n.a. |
| Q4 2014 | 24 | $18.3bn | n.a. | n.a. |
| Q1 2015 | 25 | $19.7bn | n.a. | n.a. |
| Q2 2015 | 24 | $20.2bn | n.a. | n.a. |
| Q3 2015 | 30 | $19.0bn | n.a. | n.a. |
| Q4 2015 | 25 | $17.8bn | n.a. | n.a. |
| Q1 2016 | 24 | $17.1bn | n.a. | n.a. |
| Q2 2016 | 34 | $14.3bn | n.a. | n.a. |
| Q3 2016 | 30 | $12.8bn | n.a. | n.a. |
| Q4 2016 | 32 | $9.3bn | n.a. | n.a. |
| Q1 2017 | 29 | $8.7bn | n.a. | n.a. |
| Q2 2017 | 20 | $9.0bn | n.a. | n.a. |
| Q3 2017 | 23 | $9.4bn | n.a. | n.a. |
| Q4 2017 | 32 | $10.5bn | n.a. | n.a. |
| Q1 2018 | 31 | $8.7bn | n.a. | n.a. |
| Q2 2018 | 21 | $8.1bn | n.a. | n.a. |
| Q3 2018 | 25 | $10.7bn | n.a. | n.a. |
| Q4 2018 | 33 | $11.4bn | n.a. | n.a. |
| Q1 2019 | 27 | $8.5bn | n.a. | n.a. |
| Q2 2019 | 25 | $8.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $9.6bn | n.a. | n.a. |
| Q4 2019 | 27 | $11.4bn | n.a. | n.a. |
| Q1 2020 | 29 | $8.1bn | n.a. | n.a. |
| Q2 2020 | 26 | $9.3bn | n.a. | n.a. |
| Q3 2020 | 29 | $8.9bn | n.a. | n.a. |
| Q4 2020 | 22 | $9.8bn | n.a. | n.a. |
| Q1 2021 | 28 | $10.3bn | n.a. | n.a. |
| Q2 2021 | 24 | $11.8bn | n.a. | n.a. |
| Q3 2021 | 28 | $11.9bn | n.a. | n.a. |
| Q4 2021 | 28 | $14.7bn | n.a. | n.a. |
| Q1 2022 | 25 | $14.4bn | n.a. | n.a. |
| Q2 2022 | 30 | $13.5bn | n.a. | n.a. |
| Q3 2022 | 28 | $13.9bn | n.a. | n.a. |
| Q4 2022 | 30 | $12.6bn | n.a. | n.a. |
| Q1 2023 | 36 | $9.6bn | n.a. | n.a. |
| Q2 2023 | 33 | $9.8bn | n.a. | n.a. |
| Q3 2023 | 33 | $11.7bn | n.a. | n.a. |
| Q4 2023 | 32 | $14.2bn | 15 | 18 |
| Q1 2024 | 21 | $14.3bn | 9 | 14 |
| Q2 2024 | 24 | $14.2bn | 16 | 8 |
| Q3 2024 | 31 | $14.2bn | 23 | 10 |
| Q4 2024 | 32 | $11.0bn | 17 | 16 |
| Q1 2025 | 29 | $19.1bn | 20 | 10 |
| Q2 2025 | 31 | $19.6bn | 19 | 12 |
| Q3 2025 | 28 | $21.9bn | 16 | 11 |
| Q4 2025 | 29 | $22.8bn | 18 | 23 |
| Q1 2026 | 32 | $21.1bn | 24 | 20 |
| Q2 2026 | 31 | $30.8bn | 18 | 24 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CVS and PM →CVS and KO →CVS and COST →Choose a stock to compare with CVS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CVS, latest filings →Back to the 13F Explorer →